BioPharma Resources

Drug Trial Radar · NCT07908654

A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

A Randomized, Observer-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, and Safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in Older Adults Aged 60 Years and Older

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 25,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

25,000

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, observer-blinded, placebo-controlled Phase III clinical trial to evaluate efficacy, immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.

Conditions

  • Respiratory Syncytial Virus (RSV)
  • Respiratory Syncytial Virus (RSV) Infection
  • RSV Vaccine

Interventions

  • LYB005Biological

    0.5 mL per dose.

  • PlaceboBiological

    0.5 mL 0.9% sodium chloride (normal saline) injection per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) from 14 days post-vaccination through the end of the first RSV seasonTime frame: From 14 days post-vaccination through the end of the first RSV season

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine)

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.